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In 2005, the US Senate declared March as deep vein thrombosis (DVT) awareness month in
the United States to increase the American public's understanding of deep vein thrombosis.1
This was triggered by the death of 39-yr-old David Bloom, a National Broadcasting Company
(NBC) reporter who died on April 6, 2003 from a massive pulmonary embolism (PE), and the
activities of his widow, Melanie Bloom.2 Two days before his death David Bloom had
developed cramping leg pain that was not recognized as a DVT2—leg DVT was only found
postmortem. He had several risk factors for DVT and PE (collectively called venous
thromboembolism [VTE)]): (1) prolonged immobility (working and sleeping in a cramped
position in a tank in the war in Iraq); (2) long distance flights between the US and Kuwait, (3)
dehydration, and (4) postmortem the discovery that he was heterozygous for the prothrombotic
variant of factor V called factor V Leiden.2 Melanie Bloom made it a mission to make the
American public aware of the symptoms of DVT.
This March edition of Arteriosclerosis, Thrombosis, and Vascular Biology contains 8 articles
focused on VTE, to highlight the efforts that are being devoted to understanding this disease.
Although the exact incidence of VTE is not clear and a variety of different incidence numbers
are used in medical and lay publications—VTE incidences in the United States per year
between 300 000 to more than 2 million are quoted by different sources3,4—it is clear that the
problem is substantial. Modeling suggests that more than 900 000 episodes of VTE occur in
the United States annually and nearly 300 000 deaths per year.5 Clearly, there is a need for the
various medial and public health communities to use more consistent presentations of incidence
data when communicating with the public and health policy makers to avoid confusion. An
effort should be undertaken in the near future to come to a consensus on what data to use.
In the first article, Dr Heit discusses the epidemiology and risk factors of VTE. It is striking
that the initial clinical presentation of PE in 25% of patients is sudden death. Noteworthy is
that the incidence of VTE increases dramatically over 45 yr of age. In light of the increase in
life expectancy in the US population, one can predict that the burden of this disease will rise
significantly in the future. Next, Dr Moll, a practicing hematologist, provides us with a clinical
perspective of VTE with examples of the clinical presentations of DVT and PE, diagnostic
approaches, and, finally, treatment. As he points out, every patient's VTE event is unique,
although there are a number of commonalities that contribute to the high incidence of mortality
and morbidity from VTE. These include (1) a lack of VTE prophylaxis or inappropriate
prophylaxis in risk situations, (2) missed or delayed diagnosis because of a lack of physicians'
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consideration of DVT and PE as possible diagnoses in patients presenting with extremity or
respiratory symptoms, (3) unawareness by the patient and the public in general of the risk
factors and symptoms of DVT and PE, and (4) suboptimal anticoagulation management in the
person with established VTE. The third article is written by Dr Gross and Dr Weitz and
discusses the anticoagulant drugs that are available for the treatment of VTE. Somewhat
surprisingly the present choices are limited to only 2 major drug classes: (1) unfractionated
heparin, low molecular weight heparin, and pentasaccharides that are used for short-term
anticoagulant therapy and are delivered intravenously or by subcutaneous injection. These
drugs enhance the ability of antithrombin to inhibit coagulation proteases; (2) oral vitamin K
antagonists that are used for long-term anticoagulation and act by reducing the activity of
several coagulation proteases. The major disadvantage of vitamin K antagonists is the need for
frequent coagulation monitoring to maintain a therapeutic level. The exciting development of
new anticoagulants, foremost the oral anticoagulants, is discussed. Recent data from the
RECORD 1 clinical study showed that the orally-available Factor Xa inhibitor rivaroxaban
reduced venous thromboembolic events from 3.7% to 1.1% compared with the low molecular
weight heparin enoxaparin in patients undergoing total hip replacement.6 In the future, these
new drugs may be used in place of both heparins and vitamin K antagonists and, if so, can be
expected to have a huge impact on the treatment of VTE. The final scientific article is by Dr
Wakefield and colleagues and discusses the mechanisms of venous thrombosis and resolution.
In contrast to arterial thrombosis that is most often triggered by rupture of atherosclerotic
plaques, the triggering events that lead to venous thrombosis are not clear. Virchow proposed
that thrombosis could be triggered by changes in the blood (thrombophilia), changes in the
vessel wall, and changes in blood flow, such as turbulent flow and stasis. Dr Wakefield and
colleagues present data supporting a role for inflammation in venous thrombosis, including the
idea that docking of P-Selectin Gly-coprotein Ligand-positive microparticles to P-selectin may
be a critical step in the process. In general, venous thrombosis has been thought to occur without
damage to the vessel wall. However, inflammatory mediators can activate the endothelium and
convert it from an anticoagulant surface to a procoagulant surface. The Figure shows a diagram
of the different factors that may conspire to initiate venous thrombosis.
Governmental activities in several countries have started to support activities raising awareness
among the public and health care providers about VTE, with the goal to decrease mortality and
morbidity. In the United States, the US Surgeon General held a workshop on DVT in May
2006, with participation of patients, clinicians and scientists, and government agencies.7 At
the meeting's conclusion the Surgeon General highlighted that “DVT and PE are critical public
health problems” and that he, therefore, authorized “the development of a Surgeon General
Call to Action on DVT.” He explained that “the goal of this effort will be not only to reach all
health professionals, including physicians, nurses, paramedics, EMTs (emergency medical
technicians), and others involved in treating this multifactorial disease, but also to reach the
public at large, so as to create greater awareness of and demand for appropriate prevention and
treatment of DVT.”7 The formal launch of this Call to Action is eagerly being awaited by
patients and the medical-scientific community.
In this edition of Arteriosclerosis, Thrombosis, and Vascular Biology representatives from the
National Institutes of Health (NIH) and the Centers for Disease Control (CDC) present an
overview of US governmental activities that are designed to foster thrombosis research and
improve prevention of VTE and its long-term complications. A number of organizations,
societies, coalitions, foundations, networks, consortia, and interest groups exist that have a
focus on thrombosis (Table). Their goals are to educate the public, patients, and health care
providers about thrombosis, improve health care delivery, research, public policy, and
advocacy. Although there are clear differences between the goals of some of these groups,
there is also much overlap in what they are trying to achieve. To optimize resources and avoid
duplication of efforts, future discussions about collaborations, partnerships, or mergers appear
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very appropriate. Patient advocacy can be a powerful tool in shaping health policy, as Randy
Fenninger discusses in his article. With 900 000 individuals in the US affected by VTE and
300 000 dying from PE every year, as well as 300 000 affected by postthrombotic syndrome,
the creation of a national patient advocacy group for thrombosis in the United States (NATT;
National Alliance for Thrombosis and Thrombophilia) in 2003 had been long overdue.
Fenninger joined NATT as a Board member in 2004 and was elected president in 2007. In the
United Kingdom, an “All Party Parliamentary Thrombosis Group” has been formed “to
promote awareness among parliamentarians about the risk and management of venous
thromboembolism (VTE); to increase knowledge of its causes, effects, treatments; and to
monitor the implementation of government initiatives and other research being
undertaken.”8 Furthermore, an independent expert working group was set up to develop a
national strategy on the prevention and treatment of VTE.9 The UK now has an annual
“National Thrombosis Week,” with the next one occurring May 12th to 16th, 2008. In this
edition of Arteriosclerosis, Thrombosis, and Vascular Biology, Dr Beverly Hunt, one of the
founders and the present Medical Director of the U.K. nonprofit organization “Lifeblood - a
Thrombosis Charity” reports on the activities in the UK to raise awareness about VTE.
Finally, however, the best research, science, treatment guidelines, and training of health care
professionals may not translate to better health outcomes, if health care delivery is
compromised. A recent study showed that the United States had the highest death rates from
treatable conditions of 19 industrialized countries studied. The authors conclude that the
reasons for this observation are unclear, but state that it is “difficult to disregard the observation
that the slow decline in US amenable mortality has coincided with an increase in the uninsured
population.”10 In 2004 there were 45.8 million uninsured individuals in the United States, ie,
approximately 1/6 of the US population.11 It is tempting to speculate that improvement in
health care access would lead to a significant improvement in the prevention and treatment of
VTE.
A number of activities are on the way to address the health threat that VTE poses. We welcome
March DVT Awareness month as one of these activities.
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Formation of a deep vein thrombus. The cartoon shows factors that may contribute to the
formation of a thrombus in a large vein, such as thrombophilia, activated endothelium, and
altered blood flow. The presence of valves in veins leads to turbulent flow and reduced
oxygenation of the valve endothelium (light green) that may activate the endothelium and allow
a thrombus to form. Once formed, the thrombus may extend along the vessel and embolize.
Valve pocket thrombi have been analyzed in femoral veins12. Red areas containing mostly red
cells and fibrin are the likely sites of origin of the thrombi, whereas the propagating thrombus
consists of platelets with fibrin borders12. A recent study of saphenous veins indicated that the
valvular endothelium has a thromboresistant phenotype compared with the endothelium of the
non-valvular venous wall13, although this resistance may be lost under pathological conditions.
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Table
Thrombosis-Interested Organizations, Listed in Order of the Year They Were Established (Other Organizations
May Exist)
Abbreviated Name Full Name Website Founded Nonprofit1
ACP American College of Phlebology www.phlebology.org 1985 Yes
AVF American Venous Forum www.venous-info.com 1988 Yes
AC Forum Anticoagulation Forum www.acforum.org 1991 Yes
TIGC Thrombosis Interest Group of Canada www.tigc.org 1991 Yes
HTRS Hemophilia and Thrombosis ResearchSociety www.htrs.org 1994 Yes
VDF Vascular Disease Foundation www.vdf.org 1998 Yes
NCBAP Nat. Certification Board forAnticoagulation Providers www.ncbap.org 1998
ClotCare2 ClotCare www.clotcare.com 2000 No
INATE Investigators Against Thromboembolism www.inate.org 2001 No
TAP4 Thrombophilia Awareness Project www.fvleiden.org/tap 2002 Yes
Lifeblood Lifeblood: The Thrombosis Charity www.thrombosis-charity.org 2002 Yes
NATT4
National Alliance for Thrombosis and
Thrombophilia www.nattinfo.org 2003 Yes
DVT Coalition DVT Coalition www.preventdvt.org 2003 No
VDC Venous Disease Coalition www.venousdiseasecoalition.org 2006 Yes
ATHN American Thrombosis and HemostasisNetwork www.athn.net 2006 Yes
NHF4 National Hemophilia Foundation www.hemophilia.org 20063 Yes
NATF North American Thrombosis Forum www.natfonline.org 2006 Yes
1
Either 501c3 (=tax-exempt educational organization) or 501c6 (=tax-exempt professional organization).
2
Education website only, not an organization.
3
Founded in 1948 for patients with bleeding disorders; in 2006 expanded its focus to also cover some thrombosis/thrombophilia issues.
4
Patient driven groups.
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